Sciencast Management’s Outlook Therapeutics OTLK Stock Holding History

Sciencast Management’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-615	Closed	-$27K	–	638
2021 Q1	$27K	Buy	+615	New	+$23.5K	0.01%	469

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

LNC

Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Sciencast Management's OTLK Position: Q2 2021 in Review

Sciencast Management sold out of Outlook Therapeutics (OTLK) in Q2 2021, closing a stake of 615 shares — an estimated $27K sold.

Sciencast Management first reported a position in OTLK in Q1 2021 and held it in 1 quarter. The position peaked at $27K in Q1 2021. 63 funds tracked by Wall St. Rank hold OTLK as of Q2 2021.

Sciencast Management reported no remaining Outlook Therapeutics position as of Q2 2021 after selling out during the quarter.
Sciencast Management sold 615 Outlook Therapeutics shares in Q2 2021, an estimated $27K.
Sciencast Management first reported a position in Outlook Therapeutics in Q1 2021 and held it in 1 quarter.
Sciencast Management's Outlook Therapeutics position peaked at $27K in Q1 2021.
63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2021.

Based on Sciencast Management's 13F filing for Q2 2021, filed 28 Jul 2021.